AbbVie Inc (ABBV)vsDecoy Therapeutics Inc. (DCOY)
ABBV
AbbVie Inc
$294.64
-0.16%
HEALTHCARE · Cap: $520.47B
DCOY
Decoy Therapeutics Inc.
$0.98
-7.56%
HEALTHCARE · Cap: $2.33M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 29000471% more annual revenue ($66.01B vs $227,630). ABBV leads profitability with a 15.7% profit margin vs 0.0%. DCOY trades at a lower P/E of 0.1x. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
DCOY
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-87.6%
Fair Value
$157.25
Current Price
$294.64
$137.39 premium
Intrinsic value data unavailable for DCOY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 36.6%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 36.6%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : DCOY
The strongest argument for DCOY centers on P/E Ratio, Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.6x leaves little room for execution misses.
Bear Case : DCOY
The primary concerns for DCOY are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ABBV profiles as a mature stock while DCOY is a value play — different risk/reward profiles.
DCOY carries more volatility with a beta of 0.74 — expect wider price swings.
ABBV is growing revenue faster at 10.3% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 25/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Decoy Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. The company is headquartered in Cambridge, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?